Fig. 9.

Attenuation of the Sirt6-ERα-FasL axis in severe osteoporosis patients. Human CD11b⁺ BMCs were treated with M-CSF (25 ng/ml) and RANKL (50 ng/ml) for 7 days. a–g Scatter plots of Sirt6 expression and various bone parameters. The coefficient of determination was used to compare the association of Sirt6 expression with bone parameters (a–e, n = 24; f–g, n = 16). h Clinical parameters of control subject and osteoporotic patients. i Human CD11b⁺ BMCs were treated with M-CSF and RANKL for 7 days, and the expression of Sirt6, ERα, and FasL proteins was analyzed using western blotting. The values of h and i are mean ± SEM. *p < 0.05 and **p < 0.01 versus control